Patient-Reported Outcomes (PROs) From the Phase 3 ARROW Study Comparing Once-Weekly versus Twice-Weekly Carfilzomib Dosing in Relapsed and Refractory Multiple Myeloma (RRMM)

被引：1
|
作者：
Moreau, Philippe [1 ]
Kumar, Shaji [2 ]
Boccia, Ralph [3 ]
Iida, Shinsuke [4 ]
Goldschmidt, Hartmut [5 ]
Cocks, Kim [6 ]
Zahlten-Kumeli, Anita [7 ]
Yucel, Emre [7 ]
Panjabi, Sumeet [7 ]
Dimopoulos, Meletios [8 ]
机构：
[1] Univ Hosp Hotel Dieu, Nantes, France
[2] Mayo Clin, Rochester, MN USA
[3] Ctr Canc & Blood Disorders, Bethesda, MD USA
[4] Nagoya City Univ, Grad Sch Med Sci, Nagoya, Aichi, Japan
[5] Univ Hosp Heidelberg, Heidelberg, Germany
[6] KCStats Consultancy, Leeds, W Yorkshire, England
[7] Amgen Inc, Thousand Oaks, CA 91320 USA
[8] Univ Athens, Sch Med, Athens, Greece
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2018年 / 18卷
关键词：
multiple myeloma; carfilzomib; once-weekly; patient-reported outcomes; quality of life;
D O I：
10.1016/j.clml.2018.07.130
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MM-138
引用
收藏
页码：S240 / S240
页数：1
相关论文
共 18 条
  • [1] Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (ARROW) and comparison with ENDEAVOR
    Takezako, Naoki
    Shibayama, Hirohiko
    Handa, Hiroshi
    Hagiwara, Shotaro
    Ozaki, Shuji
    Suzuki, Kenshi
    Kosugi, Hiroshi
    Ri, Masaki
    Sugiura, Isamu
    Choi, Ilseung
    Miyamoto, Toshihiro
    Iida, Shinsuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (02) : 219 - 230
  • [2] A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly
    Leleu, Xavier
    Chari, Ajai
    Richard, Shambavi
    Khurana, Monica
    Yusuf, Akeem
    Usmani, Saad Z.
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (12) : 1049 - 1058
  • [3] Trial in Progress: Once-Weekly vs Twice-Weekly Carfilzomib (K) Dosing in Combination with Lenalidomide (R) and Dexamethasone (d) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Leleu, Xavier
    Beksac, Meral
    Mateos, Maria-Victoria
    Pour, Ludek
    Weisel, Katja
    Coriu, Daniel
    Obreja, Michaela
    Goldrick, Amanda
    Dimopoulos, Meletios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S332 - S333
  • [4] Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR
    Naoki Takezako
    Hirohiko Shibayama
    Hiroshi Handa
    Shotaro Hagiwara
    Shuji Ozaki
    Kenshi Suzuki
    Hiroshi Kosugi
    Masaki Ri
    Isamu Sugiura
    Ilseung Choi
    Toshihiro Miyamoto
    Shinsuke Iida
    International Journal of Hematology, 2021, 113 : 219 - 230
  • [5] Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly
    Braun, J.
    McHugh, N.
    Singh, A.
    Wajdula, J. S.
    Sato, R.
    RHEUMATOLOGY, 2007, 46 (06) : 999 - 1004
  • [6] Once-weekly (70 mg/m2) vs twice-weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, ARROW, and CHAMPION-1 trials
    Moreau, Philippe
    Stewart, Keith A.
    Dimopoulos, Meletios
    Siegel, David
    Facon, Thierry
    Berenson, James
    Raje, Noopur
    Berdeja, Jesus G.
    Orlowski, Robert Z.
    Yang, Hui
    Ma, Haijun
    Klippel, Zandra
    Zahlten-Kumeli, Anita
    Mezzi, Khalid
    Iskander, Karim
    Mateos, Maria-Victoria
    CANCER MEDICINE, 2020, 9 (09): : 2989 - 2996
  • [7] Efficacy and Safety of Carfilzomib, Dexamethasone, Daratumumab (KdD) Twice-Weekly at 56 mg/m2 and Once-Weekly at 70 mg/m2 in Relapsed or Refractory Multiple Myeloma (RRMM): Cross-Study Comparison of the CANDOR and EQUULEUS studies
    Leleu, Xavier
    Beksac, Meral
    Chou, Takaaki
    Dimopoulos, Meletios
    Yoon, Sung-Soo
    Prince, Henry Miles
    Pour, Ludek
    Shelekhova, Tatiana
    Chari, Ajai
    Khurana, Monica
    Obreja, Mihaela
    Qi, Ming
    Oriol, Albert
    Siegel, David
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S288 - S288
  • [8] Safety and Efficacy of Once-Weekly Carfilzomib (K) Dosing in Frail Patients (pts): A Subgroup Analysis from the Phase 3 ARROW Study
    Mateos, Maria-Victoria
    Ludwig, Heinz
    Kumar, Shaji
    Rosenbaum, Cara
    Huang, Mei
    Goldrick, Amanda
    Blaedel, Julie
    Dimopoulos, Meletios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S320 - S321
  • [9] Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and ARROW Trials
    Dimopoulos, Meletios A.
    Moreau, Philippe
    Iida, Shinsuke
    Huang, Shang-Yi
    Takezako, Naoki
    Chng, Wee Joo
    Zahlten-Kumeli, Anita
    Sersch, Martina A.
    Li, Julia
    Huang, Mei
    Lee, Jae Hoon
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 110 (04) : 466 - 473
  • [10] Safety and efficacy of once-weekly carfilzomib (K) dosing in frail patients (pts): a subgroup analysis from the phase 3 ARROW study
    Mateos, Maria-Victoria
    Ludwig, Heinz
    Kumar, Shaji
    Rosenbaum, Cara
    Huang, Mei
    Goldrick, Amanda
    Blaedel, Julie
    Dimopoulos, Meletios A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10) : E31 - E32
12